-
2008
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
-
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
-
Available Positions
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and 2 compounds in pre-clinical development
Since the founding in 1998, one of Zealand Pharma’s product candidates has advanced into Phase III clinical trials: ZP10 (AVE0010) for type 2 diabetes (licensed to Sanofi-Aventis Deutschland GmbH). Two compounds, ZP120 for isolated systolic hypertension and ZP1480/AP214 for post-surgical organ failure (licensed to Action Pharma A/S), have reached Phase II clinical trials. Three product candidates, ZP10-LA (AVE0010-Long Acting) for type 2 diabetes (licensed to Sanofi-Aventis Deutschland GmbH), ZP1846 for chemotherapy-induced diarrhea and ZP1609 (GAP-134) for atrial fibrillation (licensed to Wyeth Pharmaceuticals), have advanced into Phase I clinical trials. Two product candidates, ZP1848 for inflammatory bowel disease and ZP2307 for osteoporosis, are in pre-clinical development. The development of Rotigaptide (ZP123, GAP-486) for arrhythmia (licensed to Wyeth Pharmaceuticals) have been terminated after completion of Phase II clinical trials. Pipeline Graph
The following table summarizes the status of Zealand Pharma's current product pipeline.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.